Marcelo Valenca

We are advising MSCI on the acquisition

We are advising Tencent on the transaction

Davis Polk advised NKT A/S in connection with its rights offering relating to 10,744,009 new shares. The offering consisted of a public offering in Denmark and a private placement to…

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $2.5 billion initial public offering of 89,333,920 of its Class A ordinary shares, which included an…

Davis Polk advised Oryzon Genomics, S.A. on its €20 million private placement of its ordinary shares pursuant to a capital increase. The offering consisted of a private placement to…

Davis Polk advised Ferguson plc in connection with its debut Rule 144A/Regulation S offering of $750 million aggregate principal amount of 4.500% notes due 2028 by Ferguson Finance plc. The…

Davis Polk advised Laboratorios Farmacéuticos Rovi, S.A. on its Rule 144A/Regulation S follow-on offering of 5,517,241 of its ordinary shares to raise gross proceeds of approximately €80…

Davis Polk advised the bookrunner in connection with the initial public offering of Cipla Quality Chemical Industries Limited on the Uganda Securities Exchange. The offering consisted of…

Davis Polk is advising Lazard & Co., Limited as sponsor to Vedanta Resources plc in connection with the entry by its Indian listed subsidiary, Vedanta Limited, into revenue sharing…